The collaboration will utilize Atavistik's AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer (NYSE:PFE), which will also have an option to ...

Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik ...

Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, ...

Atavistik Bio enters research collaboration with Pfizer to accelerate discovery of novel precision allosteric therapeutics: Cambridge, Massachusetts Friday, January 3, 2025, 15:00 ...

(RTTNews) - Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to accelerate the discovery of novel precision ...

Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik ...

Collaboration with Pfizer will enable Atavistik Bio to extend the reach of its platform to potentially address a broader range of oncology indications, while simultaneously progressing its ...